5 recruiting, 2 active not recruiting, 2 completed. 6 Phase 1, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Completed 2, Active not recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Pelabresib: new trials by email Literature Review of Pelabresib trials Research Report on Pelabresib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants Pelabresib, Phenytoin, Itraconazole - Healthy Participants | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-09-02 | 2026-09-22 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies pelabresib, repaglinide, midazolam - Advanced Malignancies | Phase 1 | Recruiting | Novartis Pharmaceuticals | 24 | 2026-06-12 | 2026-10-09 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-10-26 |
| Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment pelabresib - Advanced Malignancies and Hepatic Impairment | Phase 1 | Recruiting | Novartis Pharmaceuticals | 24 | 2026-05-19 | 2026-09-18 |
| Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis Pelabresib, Ruxolitinib - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 3 | 2026-04-15 | 2026-09-09 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-06-11 |
| Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies Pelabresib - Advanced Malignancies, Solid Tumor | Phase 1 | Completed | Constellation Pharmaceuticals | 35 | 2021-07-20 | 2025-07-28 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
Primary Myelofibrosis (4) · Hematologic Neoplasms (2) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Precancerous Conditions (1) · Preleukemia (1) · Thrombocythemia, Essential (1)
Novartis Pharmaceuticals (7) · Constellation Pharmaceuticals (2)
Italy (6) · France (5) · Spain (5) · United Kingdom (5) · United States (5) · Belgium (4) · Netherlands (4) · Canada (3) · Germany (3) · Poland (3) · Australia (2) · Austria (2) · Czechia (2) · Japan (2) · Malaysia (2)
PMID 35950489, PMID 36881782, PMID 37530627, PMID 38259250, PMID 40065169
2025 (3), 2023 (2), 2018 (1)